ADARx seeks $1.74 billion valuation in US IPO

ADARx Pharmaceuticals is targeting a valuation of $1.74 billion in its planned US initial public offering, according to coverage of the deal. The move would bring a developer of RNA-based medicines into the public equity markets, where appetite for early-stage biotechnology has been uneven.

The company operates in a field that aims to influence how cells make proteins by acting on RNA rather than DNA. Such approaches have attracted attention because they may reach biological targets that conventional small molecules and antibodies struggle to address. That promise carries heavy research costs and long timelines before any treatment reaches patients.

A listing at that valuation would rank ADARx among the more closely watched biotech entrants of the current window. Terms such as the number of shares offered, the price range and the final timing are usually set closer to the debut, and the outcome can shift with demand during the roadshow.

For prospective shareholders, the offering serves as a test of willingness to back platform-stage drugmakers whose science is still being proven in trials. Recent biotech debuts have produced mixed results, with some deals drawing strong interest and others postponed or withdrawn when market conditions turned less hospitable.